Amlexanox - Abeona Therapeutics

Drug Profile

Amlexanox - Abeona Therapeutics

Alternative Names: Amlexanox mucoadhesive liquid - PlasmaTech Biopharmaceuticals; LexaGard

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Access Pharmaceuticals
  • Developer Abeona Therapeutics
  • Class Aminopyridines; Anti-inflammatories; Antiallergics; Antiulcers; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Barrett's oesophagus; Oesophagitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Barrett's-oesophagus in USA (PO, Liquid)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Oesophagitis in USA (PO, Liquid)
  • 08 Apr 2014 Clinical trials in Barrett's oesophagus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top